- FDA granted full approval to Zymeworks’ zanidatamab for second-line HER2-amplified biliary tract cancer on October 7, 2026, the company’s first-ever regulatory green light.
- Zanidatamab posted a 41.3% objective response rate in the pivotal HERIZON-BTC-01 trial, a strong efficacy signal in a historically treatment-resistant cancer type.
- Peak sales across all indications are estimated at $800M–$1.2B USD, with Jazz Pharmaceuticals holding commercialization rights under a deal worth up to $1.76B USD.
- ZYME shares jumped ~34% pre-market; a Health Canada submission is planned for Q1 2027, extending the catalyst runway for Canadian investors on the TSX.
Vancouver-based Zymeworks (TSX/NYSE: ZYME) received full FDA approval on October 7, 2026, for zanidatamab (brand name: Ziihera) as a second-line treatment for adults with HER2-amplified biliary tract cancer (BTC) — a rare but aggressive gastrointestinal malignancy with very limited prior treatment options. The approval covers patients who have progressed on gemcitabine-based chemotherapy, a population estimated at roughly 12,000 to 15,000 in the United States annually. This is Zymeworks’ first regulatory approval in any jurisdiction, marking a pivotal inflection point for the company’s commercial pipeline.
What the Drug Does and Why It Matters
Zanidatamab is a bispecific antibody that simultaneously binds two distinct sites on the HER2 receptor, a mechanism Zymeworks developed using its proprietary Azymetric platform. In the pivotal HERIZON-BTC-01 trial, zanidatamab demonstrated a confirmed objective response rate (ORR) of 41.3% and a median duration of response of 12.9 months in HER2-amplified BTC patients — data the FDA cited as the clinical basis for approval. HER2 amplification occurs in approximately 15–20% of BTC cases, meaning the addressable patient pool is a targeted subset rather than the broader cancer population. Biliary tract cancers include cholangiocarcinoma and gallbladder carcinoma, both notoriously difficult to treat in later lines of therapy.
Commercial Opportunity and Competitive Landscape
Analysts at Canaccord Genuity and Bloom Burton peg the global BTC treatment market at approximately $1.4 billion USD (~$2.0 billion CAD) by 2029, with zanidatamab positioned to capture a meaningful share given its first-mover advantage in the HER2-amplified subset. Peak annual sales estimates for zanidatamab across all indications — which include ongoing Phase 3 studies in HER2-positive gastroesophageal adenocarcinoma (GEA) — range from $800 million to $1.2 billion USD, according to consensus pipeline models. Zymeworks’ key commercial partner is Jazz Pharmaceuticals, which holds ex-U.S. and U.S. co-commercialization rights under a 2023 collaboration deal worth up to $1.76 billion USD in milestones. Direct competition in the HER2-BTC space remains limited: Enhertu (trastuzumab deruxtecan, AstraZeneca/Daiichi Sankyo) has demonstrated activity in HER2-positive solid tumors broadly but does not yet hold a BTC-specific label, giving zanidatamab a clear near-term window.
Stock Reaction and Long-Term Thesis
ZYME shares surged approximately 34% in pre-market trading on October 8, 2026, recovering from a prolonged period of multiple compression that had seen the stock trade near 52-week lows ahead of the decision. At a USD/CAD rate of 1.4253, Zymeworks’ U.S.-listed shares — trading around $18.40 USD pre-market — translate to roughly $26.23 CAD on the TSX. The broader biotech tape was essentially flat, with XBI down 0.44% and IBB up 0.12%, suggesting the ZYME move is fundamentally driven rather than sector-wide sentiment. For long-term investors, the critical catalyst to watch is the Health Canada submission timeline: Zymeworks has indicated it plans a Canadian regulatory filing within Q1 2027, which would bring the therapy home to Canadian oncology clinics and further validate the company’s dual-listing profile.
| Metric | Detail |
|---|---|
| Approval Date | October 7, 2026 (FDA) |
| Indication | 2L HER2-amplified Biliary Tract Cancer |
| Trial ORR | 41.3% (HERIZON-BTC-01) |
| Peak Sales Estimate | $800M–$1.2B USD (all indications) |
| Global BTC Market (2029E) | ~$1.4B USD (~$2.0B CAD) |
| ZYME Pre-Market Move | +34% (~$18.40 USD / ~$26.23 CAD) |
The BTC approval also de-risks zanidatamab’s broader GEA program, where a Phase 3 readout is expected in H1 2027. A positive result there would substantially expand the addressable market and likely reignite institutional accumulation in a name that has been underloved on Bay Street. Canadian retail investors with biotech exposure should note that ZYME trades on both the TSX and NYSE, offering domestic access without currency conversion friction.
